MRVI
Maravai LifeSciences Holdings, Inc. Healthcare - Biotechnology Investor Relations →
Maravai LifeSciences Holdings, Inc. (MRVI) closed at $2.98 as of 2026-03-20, trading 68.5% below its 200-week moving average of $9.45. This places MRVI in the extreme value zone. The stock is currently moving closer to the line, down from -67.9% last week. The 14-week RSI sits at 40, indicating neutral momentum.
A big spike in selling this week — 2.4x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.
Over the past 230 weeks of data, MRVI has crossed below its 200-week moving average 3 times. On average, these episodes lasted 73 weeks. The average one-year return after crossing below was -58.2%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $1096 million, MRVI is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -48.6%. The stock trades at 2.0x book value.
Share count has increased 10.4% over three years, indicating dilution.
Over the past 4.5 years, a hypothetical investment of $100 in MRVI would have grown to $7, compared to $150 for the S&P 500. MRVI has returned -44.5% annualized vs 9.5% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 3 open-market purchases totaling $1,880,243. Multiple insiders purchased within a 30-day window — a cluster buy pattern that historically signals management confidence in the company's prospects. Notably, these purchases occurred while MRVI is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been declining at a -100% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: MRVI vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After MRVI Crosses Below the Line?
Across 3 historical episodes, buying MRVI when it crossed below its 200-week moving average produced an average return of -59.0% after 12 months (median -60.0%), compared to -8.3% for the S&P 500 over the same periods. After 24 months, the average return was -81.3% vs +11.0% for the index.
Each line shows $100 invested at the moment MRVI crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
MRVI has crossed below its 200-week MA 3 times with an average 1-year return of +-58.2% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Nov 2021 | Nov 2021 | 3 | 9.7% | -55.7% | -91.5% |
| Jan 2022 | Feb 2022 | 8 | 36.5% | -60.6% | -91.1% |
| Mar 2022 | Ongoing | 209+ | 90.3% | Ongoing | -91.8% |
| Average | 73 | — | +-58.2% | — |
Frequently Asked Questions
Is MRVI below its 200-week moving average?
Yes. As of 2026-03-20, Maravai LifeSciences Holdings, Inc. (MRVI) is trading 68.5% below its 200-week moving average of $9.45. The current price is $2.98.
What is MRVI's 200-week moving average price?
Maravai LifeSciences Holdings, Inc.'s 200-week moving average is $9.45 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when MRVI drops below its 200-week moving average?
MRVI has crossed below its 200-week moving average 3 times in our data. The average one-year return after these crossings was -58.2%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 73 weeks on average.
Is MRVI a good value right now?
Here's what our data says about MRVI as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 40. Free cash flow is currently negative. Return on equity is -48.6%. Price-to-book is 2.0x. This is not a buy or sell recommendation — always do your own research.
How does MRVI compare to the S&P 500?
Over the past 4.5 years, $100 invested in MRVI would have grown to $7, compared to $150 for the S&P 500. That's -44.5% annualized vs 9.5% for the index. MRVI has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20